Physician profile
Charles E Olson
NPI 1699736553
$11,618.99
in general payments reported to CMS, 2019-2025
40 companies · $992 in 2025
The $992 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,140 · 2020: $1,989 · 2021: $904 · 2022: $928 · 2023: $3,299 · 2024: $1,367 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627 · Travel and Lodging: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,626.61 |
| Travel and Lodging | $2,031.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,895.84 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $2,223.98 | 2019-2025 | Aveir, Mitraclip, Triclip |
| Medtronic, INC. | $1,476.97 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Complete Se Vascular |
| Boston Scientific Corporation | $819.67 | 2019-2025 | Avvigo Guidance System, General - Atherectomy, Samurai Rc |
| Medtronic Vascular, INC. | $779.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $472.26 | 2019-2025 | |
| Abiomed | $458.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $167.13 | 2019-2021 | |
| Philips North America LLC | $158.88 | 2020 | |
| Amgen INC. | $127.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.36 | 2019-2024 | Wainua |
| Amarin Pharma, INC. | $107.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.37 | 2019-2024 | Jardiance |
| Bridgebio Pharma, INC. | $65.82 | 2025 | Attruby |
| Cardiva Medical, INC. | $58.67 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
Show all 37 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.